General Updates

14th July 2026 IOLCP/CGC/2026 National Stock Exchange of India Ltd. BSE Limited Exchange Plaza, Plot no. C/1, G Block, Phiroze Jeejeebhoy Towers, Bandra-Kurla Complex, Bandra (E) Dalal Street Mumbai - 400 051 Mumbai – 400 001 Security Symbol: IOLCP Security Code: 524164 Subject: Approval from NMPA, China for Clopidogrel Bisulfate API Dear Sir/Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform you that the Centre for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), China, has approved the Company's API product “Clopidogrel Bisulfate”, on 14th July 2026. This approval is in addition to the valid Certificate of Suitability (CEP) already held by the Company for Clopidogrel Bisulfate, further strengthening the Company's regulatory portfolio and expanding its access to the Chinese pharmaceutical market. This is for your information and records. Thanking You, Yours faithfully, for IOL Chemicals and Pharmaceuticals Limited Abhay Raj Singh Sr. Vice President & Company Secretary